CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Doxofylline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06346691
NCT06346691Phase 4Completed

Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease : a Randomized Crossover Study

Thammasat University·interventional·Posted Apr 4, 2024·Updated Jan 20, 2025

In Brief

A Phase 4 clinical trial evaluating Doxofylline and Procaterol for COPD. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to determine if doxofylline and procaterol are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs. The main questions it aims to answer are: * Does doxofylline demonstrate a comparable bronchodilator effect to procaterol in COPD participants? * What medical problems do participants experience when taking doxofylline and procaterol?"

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesThailand
Collaborators--

Timeline

Phase 4CompletedFinished
20252026
First PostedApr 4, 2024
Enrollment StartMar 1, 2024
Primary CompletionOct 31, 2024
Study CompletionNov 15, 2024
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 2.2 years ago

Interventions

Doxofyllinedrug

Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.

Procateroldrug

Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.